Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 52.93% is in line with its 5-year average of 48.74%, around the middle of its 5-year range (-61.78%–111.44%).
10.98% below its 12-month average of 59.46%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 34.25%.
EBITDA MARGIN
52.93%
EBITDA MARGIN AVG TTM
59.46%
EBITDA MARGIN AVG 3Y
52.09%
EBITDA MARGIN AVG 5Y
48.74%
EBITDA MARGIN AVG 10Y
36.78%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-10.98%
CURRENT VS 3Y AVG
+1.61%
CURRENT VS 5Y AVG
+8.61%
CURRENT VS 10Y AVG
+43.91%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Collegium Pharmaceutical, Inc.
Market Cap
$709.36M
EBITDA Margin
52.93%
TTM Avg
59.46%
3Y Avg
52.09%
5Y Avg
48.74%
Market Cap
$711.21M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$704.20M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$723.48M
EBITDA Margin
-414.93%
TTM Avg
-258.43%
3Y Avg
-185.54%
5Y Avg
-212.52%
Market Cap
$726.75M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
Market Cap
$689.85M
EBITDA Margin
-483.37%
TTM Avg
-288.65%
3Y Avg
-1202.83%
5Y Avg
-970.15%
Market Cap
$688.73M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$688.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$684.40M
EBITDA Margin
-547.98%
TTM Avg
-848.64%
3Y Avg
-1500.78%
5Y Avg
-1508.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. (COLL) | $709.36M | 52.93% | 59.46% | 52.09% | 48.74% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Cytek Biosciences, Inc. (CTKB)vs › | $704.20M | -14.10% | -9.55% | -6.60% | -0.48% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $723.48M | -414.93% | -258.43% | -185.54% | -212.52% |
| Candel Therapeutics, Inc. (CADL)vs › | $726.75M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| Wave Life Sciences Ltd. (WVE)vs › | $689.85M | -483.37% | -288.65% | -1202.83% | -970.15% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.73M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $688.30M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $684.40M | -547.98% | -848.64% | -1500.78% | -1508.87% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.91M | N/A | N/A | N/A | N/A |
Gross Margin
60.0%
EBITDA Margin
52.9%
Operating Margin
19.6%
Net Margin
5.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 34.25% |
| 2026-03-31 | 45.42% |
| 2025-12-31 | 111.44% |
| 2025-09-30 | 57.38% |
| 2025-06-30 | 48.78% |
| 2025-03-31 | 44.02% |
| 2024-12-31 | 52.01% |
| 2024-09-30 | 48.08% |
| 2024-06-30 | 57.09% |
| 2024-03-31 | 58.59% |
| 2023-12-31 | 64.88% |
| 2023-09-30 | 60.07% |
| 2023-06-30 | 54.51% |
| 2023-03-31 | 43.38% |
| 2022-12-31 | 42.32% |
| 2022-09-30 | 45.99% |
| 2022-06-30 | 40.10% |
| 2022-03-31 | 11.49% |
| 2021-12-31 | -61.78% |
| 2021-09-30 | 39.82% |
| 2021-06-30 | 40.55% |
| 2021-03-31 | 43.81% |
| 2020-12-31 | 42.05% |
| 2020-09-30 | 46.25% |
| 2020-06-30 | 42.97% |
| 2020-03-31 | 20.33% |
| 2019-12-31 | 2.04% |
| 2019-09-30 | -3.44% |
| 2019-06-30 | -1.53% |
| 2019-03-31 | -8.21% |
| 2018-12-31 | 36.55% |
| 2018-09-30 | 30.46% |
| 2018-06-30 | 34.51% |
| 2018-03-31 | 26.35% |
| 2017-12-31 | -161.69% |
| 2017-09-30 | -111.28% |
| 2017-06-30 | -593.65% |
| 2017-03-31 | -1057.46% |
| 2016-12-31 | -2093.94% |
| 2016-09-30 | -6413.97% |
